USPTO serial 99835325
HALOZYME
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GEBHARDT, JACQUELINE D
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with HALOZYME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA, US
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gene K. Park
Gene K. Park Morgan, Lewis & Bockius LLP600 Montgomery Street, Suite 2300San Francisco, CA 94111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug delivery agents in the form of liquid for subcutaneous delivery that facilitate the delivery of pharmaceutical preparations; enzymes for medical purposes, namely, for facilitating delivery of fluids or pharmaceuticals; drug delivery agents consisting of pharmaceuticals containing enzymes that facilitate delivery of fluids and a wide range of pharmaceuticals; Pharmaceutical preparations for use in the treatment and prevention of metabolic conditions and disorders, endocrine conditions and disorders, diabetes, diabetic complications, hormonal diseases and disorders, dermatological conditions and disorders, and for the treatment of cancer and in hydration; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in aesthetic skin treatments; Hyaluronic acid for pharmaceutical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures; enzymes for medical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures | ACTIVE | — |
| 035 | Administration of a discount program enabling patients to obtain discounts on prescription drugs through use of a discount card provided by a copay discount program; business administration of a program enabling patients to obtain discounts on prescription drugs through a cash-pay program for uninsured and underinsured patients | ACTIVE | — |
| 036 | Insurance benefits verification and prior authorization assistance in the health industry; copay assistance programs, namely, providing financial assistance to uninsured and underinsured patients for prescription medications | ACTIVE | — |
| 042 | Scientific research and development services for the integration of technologies, therapies, and other systems for pharmaceuticals and drug delivery systems | ACTIVE | — |
| 044 | Providing medical information in the field of subcutaneous fluid administration; providing medical information in the field of subcutaneous delivery of a wide range of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Halozyme, Inc.
- Other trademarks owned by Halozyme, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HALOZYME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 27, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 21, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 18, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2026 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 17, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 20, 2026 | NWAP | NEW APPLICATION ENTERED | — |